Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Earle Bain"'
Autor:
Louis B. Nabors, David A. Reardon, John Simes, Lisa Roberts-Rapp, Ho-Jin Lee, Nicholas Butowski, Tobias Walbert, Andrew B. Lassman, Helen Wheeler, Priya Kumthekar, Andrew M. Scott, Peter Ansell, Tom Mikkelsen, Marta Penas-Prado, Kyriakos P. Papadopoulos, Martin J. van den Bent, Earle Bain, Zarnie Lwin, Erica Gomez, David Maag, Ryan Merrell, Hui K Gan, Hao Xiong, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy & Pharmacology, 80(6), 1209-1217. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff65c6833473b7cdb380bda35882ca5
Autor:
Martin J. van den Bent, Peter Ansell, Paul Clement, Iris de Heer, Earle Bain, Annemiek M E Walenkamp, Juan Manuel Sepúlveda, Jim Looman, Michael Weller, Pim J. French, Marica Eoli, Marie Morfouace, Enrico Franceschi, Jean-Sebastien Frenel, Thierry Gorlia, Johan M. Kros
Publikováno v:
Neuro-Oncology, 21(10), 1263-1272. Oxford University Press
Neuro Oncol
Neuro Oncol
Background Precision medicine trials targeting the epidermal growth factor receptor (EGFR) in glioblastoma patients require selection for EGFR-amplified tumors. However, there is currently no gold standard in determining the amplification status of E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2ef61d763f9a393478b507fc0475fbb
https://doi.org/10.1093/neuonc/noz096
https://doi.org/10.1093/neuonc/noz096
Autor:
Peter Ansell, Lisa Roberts-Rapp, Priya Kumthekar, Ho-Jin Lee, Marta Penas-Prado, Louis B. Nabors, David A. Reardon, Hao Xiong, Earle Bain, Erica Gomez, David Maag, Kyriakos P. Papadopoulos, Martin J. van den Bent, Tobias Walbert, Nicholas Butowski, Andrew B. Lassman, Ryan Merrell, Zarnie Lwin, Hui K Gan, Kyle D. Holen, Helen Wheeler, Andrew M. Scott, Tom Mikkelsen, John Simes
Publikováno v:
Neuro-Oncology, 21(1), 106-114. Oxford University Press
Neuro-Oncology
Neuro-Oncology
Background Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) ampl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b826fa234de182c56cd50693251c3b03
https://pure.eur.nl/en/publications/a6d634d2-cf77-41a8-85f8-99e93079ff3f
https://pure.eur.nl/en/publications/a6d634d2-cf77-41a8-85f8-99e93079ff3f
Autor:
Jim Looman, Wies Vallentgoed, Johan M. Kros, Pim J. French, Peter Ansell, Annemiek M E Walenkamp, Marie Morfouace, Earle Bain, Youri Hoogstrate, Vassilis Golfinopoulos, Juan Manuel Sepúlveda, Jean-Sebastien Frenel, Paul Clement, Martin J. van den Bent, Martin E. van Royen, Marica Eoli, Enrico Franceschi, Thierry Gorlia, Iris de Heer, Micheal Weller, Maurice de Wit
Publikováno v:
Neuro-Oncology Advances, 2(1):vdz051. Oxford University Press
Neuro-oncology advances, 2(1)
Neuro-oncology Advances
Neuro-oncology advances, 2(1)
Neuro-oncology Advances
BackgroundThe randomized phase II INTELLANCE-2/EORTC_1410 trial on EGFR-amplified recurrent glioblastomas showed a trend towards improved overall survival when patients were treated with depatux-m plus temozolomide compared with the control arm of al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abaf9b1c03e19dee075fff4e73dd5698
https://doi.org/10.1093/noajnl/vdz051
https://doi.org/10.1093/noajnl/vdz051
Autor:
Clemens Seidel, Matthias Preusser, Antje Wick, Dmitry Bentsion, Minhee Won, Walter J. Curran, Suvajit Samanta, Earle Bain, Giuseppe Lombardi, Andrés F. Cardona, Tony J. C. Wang, Stephanie L. Pugh, Golnaz Moazami, Peter Ansell, Craig Gedye, Marian S. Macsai, Filip de Vos, Peixin Zhang, Mark R. Gilbert, Sigmund Hsu, Kenneth Aldape, Hui K Gan, Vincent Blot, Andrew B. Lassman, Richard A. Peterson, Erik P. Sulman, Madan Gopal Kundu, Minesh P. Mehta, Christine Lebrun-Frenay, Michael A. Vogelbaum
Publikováno v:
Neuro Oncol
BACKGROUND Approximately 50% of nGBMs harbor EGFR-amp. Depatuxizumab mafodotin (depatux-m) is an antibody drug conjugate: a monoclonal antibody that binds activated EGFR (wild-type and EGFRvIII mutant) linked to a microtubule-inhibitor toxin. Pre-cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96fb51b9cf133d6802c7a8c09ee05fd2
https://europepmc.org/articles/PMC6847524/
https://europepmc.org/articles/PMC6847524/
Autor:
Minghao Song, Andrew B. Lassman, Manabu Kinoshita, Lisa Roberts-Rapp, Christopher Ocampo, Pim J. French, Peter Ansell, Michael A. Vogelbaum, Martin J. van den Bent, Marica Eoli, Tony J. C. Wang, Peixin Zhang, Yoshihiro Muragaki, Kenneth Aldape, Walter J. Curran, Yoshitaka Narita, Earle Bain, Jim Looman, Annemiek M E Walenkamp, Minesh P. Mehta
Publikováno v:
JOURNAL OF NEURO-ONCOLOGY, 144(1), 205-210. SPRINGER
Journal of Neuro-Oncology, 144(1), 205-210. Kluwer Academic
J Neurooncol
Journal of Neuro-Oncology, 144(1), 205-210. Kluwer Academic
J Neurooncol
Epidermal growth factor receptor (EGFR) amplification has been reported to occur in ~ 50% of glioblastomas (GBMs). We are conducting several global studies that require central testing for EGFR amplification during screening, representing an opportun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23a308690de23aa5dd947be5af538821
https://research.rug.nl/en/publications/a185ad68-f0a7-45b3-8647-bbf58ab6b574
https://research.rug.nl/en/publications/a185ad68-f0a7-45b3-8647-bbf58ab6b574
Autor:
Christine Lebrun-Frenay, Giuseppe Lombardi, Craig Gedye, Andrew B. Lassman, Madan G. Kundu, Mark R. Gilbert, Andrés F. Cardona, Erik P. Sulman, Clemens Seidel, Peter Ansell, Marian S. Macsai, Matthias Preusser, Hui K Gan, Kenneth Aldape, Sigmund Hsu, Richard A. Peterson, Golnaz Moazami, Jeffrey S. Wefel, Suvajit Samanta, Michael A. Vogelbaum, Stephanie L. Pugh, Yaakov Stern, Antje Wick, Dmitry Bentsion, Minesh P. Mehta, Earle Bain, Filip de Vos, Terri S. Armstrong, Vincent Blot, Walter J. Curran, Tony J. C. Wang, Minhee Won
Publikováno v:
Neuro Oncol
RTOG 3508/AbbVie M13-813/INTELLANCE-1 was a phase 3 trial of depatuximab-mafodotin (depatux-m, formerly ABT-414) that accrued 639 patients with EGFR-amplified newly diagnosed GBM. At the pre-specified interim OS analysis, the futility criteria were m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dce713a3b948abb37c94823f56685d9b
https://doi.org/10.1093/neuonc/noaa215.217
https://doi.org/10.1093/neuonc/noaa215.217
Autor:
James Lee, Peter Ansell, Andrew B. Lassman, Lisa Roberts-Rapp, Martin J. van den Bent, Kyle D. Holen, Jim Looman, Earle Bain, Christopher Ocampo, Erica Gomez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e709ba949f05224e21038246c72ec084
https://europepmc.org/articles/PMC5693085/
https://europepmc.org/articles/PMC5693085/
Autor:
Erica Gomez, Golnaz Moazami, Maria Guseva, Christopher Ocampo, Earle Bain, Marian S. Macsai, Stella Kim
Publikováno v:
Neuro-Oncology. 20:vi15-vi16
BACKGROUND: Depatuxizumab mafodotin (depatux-m, formerly ABT-414), is an antibody-drug conjugate comprised of an EGFR-targeted antibody, a non-cleavable linker maleimidocaproyl, and the microtubule inhibitor monomethylauristatin F. Promising antitumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::260b15e7ea3410f1c21cccc3b9923950
https://doi.org/10.1093/neuonc/noy148.055
https://doi.org/10.1093/neuonc/noy148.055
Autor:
Hao Xiong, Jan Peter de Geus, Jim Looman, Peter Ansell, Darren Hargrave, Martin J. van den Bent, Vassilis Golfinopoulos, Earle Bain, Winand N.M. Dinjens, Fiona Dungey
Publikováno v:
Neuro-Oncology. 20:i91-i92
INTRODUCTION: Pediatric high grade gliomas (HGGs) and diffuse intrinsic pontine gliomas have no adequate therapy and are almost universally fatal. Depatuxizumab mafodotin (depatux-m) is an antibody-drug conjugate, comprised of anti-EGFR antibody link
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfbc43fce3b42a4cc813b866fbbb252
https://doi.org/10.1093/neuonc/noy059.287
https://doi.org/10.1093/neuonc/noy059.287